Colgate-Palmolive Company has reached an agreement to acquire brands PCA Skin and EltaMD.

Carried out in two separate transactions, the deals will enable the firm to move into the professional skincare category.

The acquisitions are part of Colgate-Palmolive Company’s strategy to focus on its existing higher-margin global personal care businesses.

PCA Skin manufactures in-office and take-home skincare products, while EltaMD is a physician-dispensed suncare brand. Both are expected to continue operating independently following completion of the transactions.

“The deals are expected to take place in Q1 2018 and are subject to customary closing conditions.”

The deals are expected to take place in Q1 2018 and are subject to customary closing conditions, including US antitrust clearance.

Colgate’s chairman, president and CEO Ian Cook said: “PCA Skin and EltaMD form an exciting combination for Colgate’s entry into the professional skincare category. We are delighted that these high-growth, high-margin brands will strengthen our global personal care business.

“Their complementary product portfolios and sales forces, strong professional support and similar distribution channels will advance Colgate’s presence in the premium global skincare category.

“Furthermore, these businesses will benefit from Colgate’s decades-long legacy of working with professional experts to deliver recommendations that benefit their patients.”

Wachtell, Lipton, Rosen & Katz served as legal advisor to Colgate-Palmolive on both transactions and Wells Fargo Securities was the exclusive financial advisor to Colgate-Palmolive on the acquisition of EltaMD.